Clinical Trial Update: A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006) [Phase 2]

View source ↗

Summary

This clinical trial update reports on a Phase 2 study of Zilovertamab Vedotin (MK-2140) as monotherapy and in combination for aggressive and indolent B-cell mal…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Follicular Lymphoma
• Mantle Cell Lymphoma
• Richter Transformation

Drugs mentioned

• Zilovertamab vedotin (zilovertamab vedotin)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING